Energy Select Sector SPDR Fund vs Zimmer Biomet Holdings Inc — how do they compare? Energy Select Sector SPDR Fund trades at $65.14 (market cap $40.84B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Energy Select Sector SPDR Fund is far larger — about 2.4× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Energy Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Energy Select Sector SPDR Fund for 67 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| XLE | ZBH | |
|---|---|---|
Market Cap | $40.84B | $16.95B |
Volume | 50,409,268 | 2,505,240 |
52-Week High | $65.93 | $103.98 |
52-Week Low | $42.61 | $79.58 |
Typical Hold Time | 67 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
XLE trades at $65.09, up 2.7% today amid bullish technical signals from moving averages, though oscillators show caution with RSI levels in overbought territory. The energy ETF faces mixed sentiment as oil prices surge above $100 due to Middle East tensions while futures traders bet on a potential 12% sector decline. Recent news highlights strategic oil reserve concerns and diesel price pressures affecting energy markets.
Outlook remains volatile with geopolitical risks driving short-term gains but fundamental headwinds from potential oil price corrections. Key risks include oil market volatility and Federal Reserve policy impacts, while technical support at $64-$65 provides near-term stability. Investors should weigh high current energy prices against recessionary pressures that could dampen demand.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →